GEPIRONE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H29N5O2.ClH
Molecular Weight	395.927
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1

InChI

InChIKey=DGOCVISYYYQFEP-UHFFFAOYSA-N

InChI=1S/C19H29N5O2.ClH/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18;/h5-7H,3-4,8-15H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	C19H29N5O2
Molecular Weight	359.4659
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM474542.pdf | http://www.prnewswire.com/news-releases/fda-rules-favorably-on-efficacy-of-travivo-gepirone-er-for-treatment-of-major-depressive-disorder-300237987.html | http://www.theinfolist.com/php/SummaryGet.php?FindGo=Gepirone | https://clinicaltrials.gov/ct2/show/NCT00000189

Gepirone (brand name Travivo) is an investigational azapirone antidepressant and anxiolytic drug in development for the treatment of major depressive disorder but has yet to be marketed. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone has been under development in the U.S. in an extended release form (referred to as Gepirone ER). It has been rejected multiple times by the FDA during the drug approval process and Phase III studies evaluating its use in the treatment of MDD were prematurely terminated. These were the initial Phase III studies of gepirone ER in MDD, and the effective dose range had not been determined. In March 2016, the FDA reversed its decision and gave gepirone ER a positive review, clearing the way for the drug to finally gain market approval in the U.S. In addition to its antidepressant and anxiolytic properties, gepirone has been found to improve symptoms of sexual dysfunction in men and women, similarly to the marketed 5-HT1A receptor agonist flibanserin. The pro-sexual effects appear to be independent of its antidepressant and anxiolytic effects. Mechanism of action studies have demonstrated that gepirone possesses a much greater selectivity for 5-HT1A receptors over dopamine D2 receptors. Long-term studies have shown that gepirone has a differential action at presynaptic (agonist) and post-synaptic (partial agonist) 5-HT1A receptors. Treatment with gepirone ER desensitizes presynaptic 5-HT1A receptors, which decreases serotonin autoregulatory inhibition and enhances activation of postsynaptic 5-HT1A receptors. As a partial agonist gepirone ER acts as an agonist when endogenous serotonin is not present and as an antagonist when endogenous serotonin is present. Overall, gepirone ER increases serotonin production when insufficient amounts are present, and decreases serotonin production when excess amounts are present. Gepirone has been tested in Phase II clinical trial as antidepressant medication for pharmacotherapy for cocaine dependent subjects.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
5-hydroxytryptamine receptor 1A 58 Target ID: P08908 Gene ID: 3350.0 Gene Symbol: HTR1A Target Organism: Homo sapiens (Human) Sources: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM474542.pdf	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cocaine-related disorders 19 Sources: https://clinicaltrials.gov/ct2/show/NCT00000189	Secondary		Phase II 1147	Unknown Approved Use Unknown
Major depressive disorder 179 Sources: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM474542.pdf	Primary		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
2.55 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.13 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
3.21 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
2.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	3-HYDROXYGEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	3-HYDROXYGEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
6.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.73 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12.03 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12.55 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
16.98 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
31.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
38.71 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
52.77 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
55.39 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
138 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	3-HYDROXYGEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
157 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24944406/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	3-HYDROXYGEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
54.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
92.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	10 mg 2 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
55.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
74 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
67.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
51.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12949996/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
55.26 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
93 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
99.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
75.69 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
2.94 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	1-(2-PYRIMIDINYL)PIPERAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8103528/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	GEPIRONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
120 mg 1 times / day steady-state, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady-state Dose: 120 mg, 1 times / day Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002	Disc. AE: Nausea... Other AEs: Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 40%) Other AEs: Dizziness (grade 1-2, 70%) Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002

AEs

AE	Significance	Dose	Population
Nausea	grade 1-2, 40% Disc. AE	120 mg 1 times / day steady-state, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady-state Dose: 120 mg, 1 times / day Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002
Dizziness	grade 1-2, 70%	120 mg 1 times / day steady-state, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: steady-state Dose: 120 mg, 1 times / day Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://link.springer.com/article/10.2165/00044011-200222120-00002

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/55191#section=BioAssay-Results Page: 21.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/55191#section=BioAssay-Results Page: 20.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/55191#section=BioAssay-Results Page: 20.0	no

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15057659/	major
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15057659/	minor
P-gp 2052	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDQxODcifX0=	yes

PubMed

Title	Date	PubMed
Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder.	2010-04-23	20412598
Emotional reactivity and cognitive performance in aversively motivated tasks: a comparison between four rat strains.	2009-12-15	20003525
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.	2009	19590732
Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models.	2008-09	19506722
Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.	2008-04	18373383
Differential response to gepirone but not to chlordiazepoxide in malnourished rats subjected to learned helplessness.	2008-01	17952336
Acute and constitutive increases in central serotonin levels reduce social play behaviour in peri-adolescent rats.	2007-12	17661017
Early response and 8-week treatment outcome in GAD.	2006	16845651
The 5-HT1A receptor and the stimulus effects of LSD in the rat.	2005-10	16025319
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.	2005-06	15960558
Novel, flexible, and conformationally defined analogs of gepirone: synthesis and 5-HT1A, 5-HT2A, and D2 receptor activity.	2005-02-15	15670928
Relapse prevention with gepirone ER in outpatients with major depression.	2005-02	15643103
[Review of antidepressants from the TCAs to the third generation drugs].	2004-12	15825674
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.	2004-08	15323591
Cellular consequences of stress and depression.	2004-06	22033809
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands.	2004-04-05	15026055
Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.	2004-03	15088636
Metabolism of the newest antidepressants: comparisons with related predecessors.	2004-02	15057659
Differential effects of the 5-HT1A agonist gepirone on food intake in rats may depend on their motivation to eat.	2003-11	14685301
Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers.	2003-09	12949996
A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.	2003-06	12860488
Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.	2003-04-19	15003431
Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.	2003-03	12716264
Human cytochromes mediating gepirone biotransformation at low substrate concentrations.	2003-03	12619053
Is there a role for 5-HT1A agonists in the treatment of depression?	2003-02-01	12559651
Influence of housing conditions on the effects of serotonergic drugs on feeding behavior in non-deprived rats.	2003	12707493
Rigid analogues of buspirone and gepirone, 5-HT1A receptors partial agonists.	2002-11	12484540
5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain.	2002-10-04	12354565
The clinical pharmacology of depressive states.	2002-03	22034133
Gepirone. Organon.	2001-08	11892924
Effects of serotonergic compounds on aqueous humor dynamics in monkeys.	2001-08	11840350
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.	2000-12	11220492
Involvement of 5-hydroxytryptamine(1A) receptors in nicotine-induced tail tremor in rats.	2000-11-10	11070179
Prenatal exposure to cocaine: effects on aggression in Sprague-Dawley rats.	1994-05	7913451
Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction.	1989	2524857
Strychnine seizure potentiation by azaspirodecanedione anxiolytics in rats.	1988-10-18	2906877

Patents

Sample Use Guides

In Vivo Use Guide

Gepirone ER (20 mg to 80 mg) was administered once per day in the morning for 8 weeks (56 days). Patients with moderate to severe depression initiated treatment by taking a 20 mg tablet once daily in the morning with food, followed by an increase to 40 mg daily between days 4 and 7. The dose could be increased to 60 mg daily after day 7, and to 80 mg daily after 14 days.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:10 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:10 GMT 2025`
Record UNII	80C9L8EP6V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EXXUA

Preferred Name

English

GEPIRONE HYDROCHLORIDE

Official Name

English

3,3-Dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]glutarimide monohydrochloride

Common Name

English

ORG-33062

Common Name

English

ORG 33062

Code

English

GEPIRONE HYDROCHLORIDE [MART.]

Common Name

English

GEPIRONE HCL

Common Name

English

Gepirone hydrochloride [WHO-DD]

Common Name

English

BMY-13805-1

Code

English

BMY 13805-1

Code

English

TRAVIVO

Brand Name

English

GEPIRONE HYDROCHLORIDE [USAN]

Common Name

English

2,6-PIPERIDINEDIONE, 4,4-DIMETHYL-1-(4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)BUTYL)-, MONOHYDROCHLORIDE

Common Name

English

TGFK07AD

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C28197